<unk>  <unk>  is the only FDA-licensed human anthrax vaccine in the United States. It is produced under the trade name BioThrax by the Emergent BioDefense Corporation (formerly known as BioPort Corporation) in Lansing, Michigan. The parent company of Emergent BioDefense is Emergent BioSolutions of Rockville, Maryland. It is sometimes called MDPH-PA or MDPH-AVA after the former Michigan Department of Public Health (MDPH; succeeded by the Michigan Department of Health and Human Services), which formerly was involved in its production.<unk>  originated in studies done in the 1950s and was first licensed for use in humans in 1970. In the US, the principal purchasers of the vaccine are the Department of Defense and Department of Health and Human Services. Ten million courses (60 million doses) of the vaccine have been purchased for the US Strategic National Stockpile in anticipation of the need for mass vaccinations owing to a future bio-terrorist anthrax attack. The product has attracted some controversy owing to alleged adverse events and questions as to whether it is effective against the inhalational form of anthrax.
Anthrax vaccine adsorbed
Plant expressed vaccine
Tuberculosis vaccines
Malaria vaccine
Salvioli's diffusing vaccine
Synthetic vaccine
Anthrax vaccines
Rabies vaccine